Meningococcal ACWY Vaccine – Epidemiology – Epidemiology | Meningococcal ACWY Vaccine – Mature Markets

Clarivate Epidemiology’s coverage of the meningococcal ACWY vaccine comprises epidemiological estimates of key patient populations in major mature pharmaceutical markets (the United States, France, Italy, Spain, and the United Kingdom). We report the eligible population recommended to receive the meningococcal ACWY vaccine for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s meningococcal ACWY vaccine forecast will answer the following question:

• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the meningococcal ACWY vaccine-eligible population over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following meningococcal ACWY vaccine patient populations:

• Meningococcal ACWY vaccine-eligible population.
• The population newly eligible for the meningococcal ACWY vaccine.

Note: Coverage may vary by country.